With the UK government on course to begin the legal process for leaving the EU, industry leaders have spoken openly about the impact. In separate teleconferences, the CEOs of AstraZeneca Plc and GlaxoSmithKline Plc (GSK) said the EMA would almost certainly have to re-locate.
